Registration number:
DNA Vetcare Limited
for the Year Ended 31 July 2025
Registration number:
DNA Vetcare Limited
for the Year Ended 31 July 2025
DNA Vetcare Limited
Contents
|
Company Information |
|
|
Group Strategic Report |
|
|
Directors' Report |
|
|
Independent Auditor's Report |
|
|
Consolidated Profit and Loss Account |
|
|
Consolidated Statement of Comprehensive Income |
|
|
Consolidated Balance Sheet |
|
|
Balance Sheet |
|
|
Consolidated Statement of Changes in Equity |
|
|
Statement of Changes in Equity |
|
|
Consolidated Statement of Cash Flows |
|
|
Statement of Cash Flows |
|
|
Notes to the Financial Statements |
DNA Vetcare Limited
Company Information
|
Directors |
Mr A G Van Heerden Mr S D Walker |
|
Registered number |
05185406 |
|
Registered office |
|
|
Auditors |
|
DNA Vetcare Limited
Group Strategic Report for the Year Ended 31 July 2025
The directors present their group strategic report for the year ended 31 July 2025.
Principal activity
The principal activity of the group is the provision of veterinary services.
Fair review of the business
The year ended 31 July 2025 has been a year of strong growth across the group as shown by the strong turnover growth achieved in the year.
The continued growth has been achieved by investing in both our staff and our facilities to ensure a high level of customer service from our talented and experienced team.
During the year, the group acquired 9 new surgeries, in addition to the 13 new surgeries acquired in 2024, including the purchase of a premises. This has increased the number of branches within the group to 48 and the group continues to explore avenues to grow the group even further.
The group's key financial and other performance indicators during the year were as follows:
|
Financial KPIs |
Unit |
2025 |
2024 |
|
Turnover growth |
% |
28.70 |
68.90 |
|
Gross profit margin |
% |
78.90 |
77.50 |
Principal risks and uncertainties
Consolidation in the industry continues, with the larger corporate entities now being joined by investors from the US and beyond. This means that competition has become more intense, and there is a constant need to keep up to date in terms of equipment, branch appearances and digital capabilities. To counter this, the group has continued its investment in equipment, refurbishments and the development of its staff.
The needs of the more demanding customer are constantly being evaluated and opportunities created. The group is committed to improve engagement with its clients by providing more services, better facilities and to improve communication.
The wider economic environment remains uncertain, reflecting ongoing inflationary pressures, cost increases and broader macroeconomic challenges. The Group has assessed its financial position and is satisfied that its resources and borrowing facilities are sufficient to withstand potential adverse conditions. Historically, the veterinary sector has demonstrated resilience during periods of economic volatility, supported in part by the increasing prevalence of pet insurance and recurring revenue streams such as preventative healthcare plans, which are less dependent on client footfall.
DNA Vetcare Limited
Group Strategic Report for the Year Ended 31 July 2025
Section 172(1) statement
The Directors understand the business, strategic targets and ever-changing market and environment that the company operates in. Strategic decisions are taken at board level, where the Directors take decisions they believe are in the best interests of the company, members and stakeholders. The board meets every month to discuss current topics across all areas of the business. They receive an overview of the current financial performance and discuss matters of importance during the board meetings.
The Directors recognise that the employees are fundamental and are integral to the business to deliver strategic ambitions. The success of the business depends on attracting, retaining, and motivating employees. Directors ensure that the company does the upmost to be a responsible employer considering pay, benefits, upkeep of health and safety requirements, and workplace environments. When making decisions, the Directors factor the implication of decisions on the employees where it is relevant and possible to do so.
The Directors recognise that in order to achieve its strategic objectives, it must have strong relationships with its customers and suppliers. The Directors receive regular information and feedback from business operations that inform them how current and emerging relationships are developing. The Directors actively seek and receive third party information indicating performance from a customer point of view. The Directors also receive regular updates on supplier activities and contract management topics.
The Directors will take into account the impact of the company's operations on the community and environment in any decision-making process where it is necessary to do. The Directors are fully aware of their legal responsibilities and obligations, including company policies which are designed to uphold the core values of DNA Vetcare Limited, and ensure all stakeholders conduct themselves as it would expect. By following these principles and guidelines, the business is conducted with the utmost integrity. Regular internal reviews take place, which help ensure that the guidelines are followed and identify any areas or processes that can be improved.
The Directors consider the best possible action in its decision-making process to deliver their strategy. When making these decisions the Directors act as fairly as they can for all members however this can mean that sometimes certain stakeholder interests may not be fully aligned.
The Board understand their duties and responsibilities individually and collectively. They have acted in accordance with their duties codified in law, which include their duty to act in a way in which they consider would be most likely to promote the success of the company to the benefit of its members whilst considering the stakeholders of the company and matters set out in section 172 (1) of the Companies Act 2006.
Approved by the
|
|
|
DNA Vetcare Limited
Directors' Report for the Year Ended 31 July 2025
The directors present their report and the for the year ended 31 July 2025.
Directors of the group
The directors who held office during the year were as follows:
Financial instruments
Objectives and policies
The group's principal financial assets are its bank balances, fixed assets and debtors. The group's credit risk is primarily attributable to its trade debtors. To mitigate this credit risk, the group uses a combination of internal credit control functions and external debt collection agencies. The accounts presented in the balance sheet are net of provisions for doubtful debts. The group does not purchase any significant goods or services in foreign currencies.
Price risk, credit risk, liquidity risk and cash flow risk
The group is exposed to fair value interest rate risk on its fixed rate borrowings and cash flow interest risk on any floating rate borrowings. In order to maintain liquidity and ensure that sufficient funds are available for ongoing operations and future developments, the group uses a mixture of long-term and short-term debt finance.
Disclosure of information to the auditor
Each director has taken steps that they ought to have taken as a director in order to make themselves aware of any relevant audit information and to establish that the company's auditor is aware of that information. The directors confirm that there is no relevant information that they know of and of which they know the auditor is unaware.
Reappointment of auditors
The auditors Moore Scarrott Audit Limited are deemed to be reappointed under section 487(2) of the Companies Act 2006.
DNA Vetcare Limited
Directors' Report for the Year Ended 31 July 2025
Statement of Directors' Responsibilities
The directors acknowledge their responsibilities for preparing the Annual Report and the financial statements in accordance with applicable law and regulations.
Company law requires the directors to prepare financial statements for each financial year. Under that law the directors have elected to prepare the financial statements in accordance with United Kingdom Generally Accepted Accounting Practice (United Kingdom Accounting Standards and applicable law). Under company law the directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the group and the company and of the profit or loss of the group for that period. In preparing these financial statements, the directors are required to:
|
• |
select suitable accounting policies and apply them consistently; |
|
• |
make judgements and accounting estimates that are reasonable and prudent; |
|
• |
state whether applicable UK Accounting Standards have been followed, subject to any material departures disclosed and explained in the financial statements; and |
|
• |
prepare the financial statements on the going concern basis unless it is inappropriate to presume that the company will continue in business. |
The directors are responsible for keeping adequate accounting records that are sufficient to show and explain the group's and the company's transactions and disclose with reasonable accuracy at any time the financial position of the group and the company and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the group and the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.
Approved by the
|
|
|
DNA Vetcare Limited
Independent Auditor's Report to the Members of DNA Vetcare Limited
Opinion
We have audited the financial statements of DNA Vetcare Limited (the 'parent company') and its subsidiaries (the 'group') for the year ended 31 July 2025, which comprise the Consolidated Profit and Loss Account, Consolidated Statement of Comprehensive Income, Consolidated Balance Sheet, Balance Sheet, Consolidated Statement of Changes in Equity, Statement of Changes in Equity, Consolidated Statement of Cash Flows, Statement of Cash Flows, and Notes to the Financial Statements, including a summary of significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' (United Kingdom Generally Accepted Accounting Practice).
In our opinion the financial statements:
• | give a true and fair view of the state of the group's and the parent company's affairs as at 31 July 2025 and of the group's profit for the year then ended; |
• | have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and |
• | have been prepared in accordance with the requirements of the Companies Act 2006. |
Basis for opinion
We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the auditor responsibilities for the audit of the financial statements section of our report. We are independent of the group in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC’s Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.
Conclusions relating to going concern
In auditing the financial statements, we have concluded that the director's use of the going concern basis of accounting in the preparation of the financial statements is appropriate.
Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the group's ability to continue as a going concern for a period of at least twelve months from when the original financial statements were authorised for issue.
Our responsibilities and the responsibilities of the directors with respect to going concern are described in the relevant sections of this report.
Other information
The directors are responsible for the other information. The other information comprises the information included in the annual report, other than the financial statements and our auditor’s report thereon. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.
In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether there is a material misstatement in the financial statements or a material misstatement of the other information. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.
We have nothing to report in this regard.
DNA Vetcare Limited
Independent Auditor's Report to the Members of DNA Vetcare Limited
Opinion on other matter prescribed by the Companies Act 2006
In our opinion, based on the work undertaken in the course of the audit:
|
• |
the information given in the Group Strategic Report and Directors' Report for the financial year for which the financial statements are prepared is consistent with the financial statements; and |
|
• |
the Group Strategic Report and Directors' Report have been prepared in accordance with applicable legal requirements. |
Matters on which we are required to report by exception
In the light of our knowledge and understanding of the company and its environment obtained in the course of the audit, we have not identified material misstatements in the Group Strategic Report and the Directors' Report.
We have nothing to report in respect of the following matters where the Companies Act 2006 requires us to report to you if, in our opinion:
• | adequate accounting records have not been kept by the parent company, or returns adequate for our audit have not been received from branches not visited by us; or |
• | the parent company financial statements are not in agreement with the accounting records and returns; or |
• | certain disclosures of directors' remuneration specified by law are not made; or |
• | we have not received all the information and explanations we require for our audit. |
Responsibilities of directors
As explained more fully in the Statement of Directors’ Responsibilities on page 6, the directors are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the directors determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.
In preparing the financial statements, the directors are responsible for assessing the company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the directors either intend to liquidate the company or to cease operations, or have no realistic alternative but to do so.
Auditor Responsibilities for the audit of the financial statements
Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor’s report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.
As part of an audit in accordance with ISAs (UK), we exercise professional judgement and maintain professional scepticism throughout the audit.
The extent to which our procedures are capable of detecting irregularities, including fraud is detailed below:
DNA Vetcare Limited
Independent Auditor's Report to the Members of DNA Vetcare Limited
We considered the nature of the company's industry and its control environment, and reviewed the company's documentation of their policies and procedures relating to fraud and compliance with laws and regulations. We also enquired of management about their own identification and assessment of the risks of irregularities.
We obtained an understanding of the legal and regulatory frameworks that the company operates in, and identified the key laws and regulation that:
- had a direct effect on the determination of material amounts and disclosures in the financial statements. These included UK Companies Act, pensions legislation, tax legislation; and
- do not have a direct effect on the financial statements but compliance with which may be fundamental to the company's ability to operate or to avoid a material penalty. These included the company's compliance with the RCVS regulations applicable to all practices and qualified nurses, GDPR, Veterinary Surgeons Act 1966, Animal Welfare Act 2006, Veterinary Medicines Regulations 2013 and The Animal Act 1986.
We discussed amongst the audit engagement team, the opportunities and incentives that may exist within the organisation for fraud and how and where fraud might occur in the financial statements.
As a result of the above, we identified the greatest potential for fraud in the following areas, and our specific procedures performed to address them are described below:
- There is a significant risk related to revenue recognition of Proactive pets income, which is a plan where a customer pay a direct debit per month and receives a set number of treatments. The revenue is recognised based on the percentage completion and therefore there will be either a deferred or accrued revenue at the end of the year. This is where there is the greatest risk of management bias. We have reviewed a sample of memberships to ensure that the revenue has been calculated correctly and that there are no cut-off errors.
- In common with all audits under ISAs (UK), we are also required to perform specific procedures to respond to the risk of management override. In addressing the risk of fraud through management override of controls, we tested the appropriateness of journal entries and other adjustments; assessed whether the judgements made in making accounting estimates are indicative of a potential bias; and evaluated the business rationale of any significant transactions that are unusual or outside the normal course of business.
In addition to the above, our procedures to respond to the risks identified included the following:
- reviewing financial statement disclosures by testing to supporting documentation to assess compliance with provisions of relevant laws and regulations described as having a direct effect on the financial statements;
- performing analytical procedures to identify any unusual or unexpected relationships that may indicate risks of material misstatement due to fraud;
- enquiring of management and external legal counsel concerning actual and potential litigation and claims, and instances of non-compliance with laws and regulations; and
- reading minutes of meetings of those charged with governance
A further description of our responsibilities is available on the Financial Reporting Council’s website at: www.frc.org.uk/auditorsresponsibilities. This description forms part of our auditor’s report.
DNA Vetcare Limited
Independent Auditor's Report to the Members of DNA Vetcare Limited
Use of our report
This report is made solely to the company’s members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the company’s members those matters we are required to state to them in an auditor’s report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the company and the company’s members as a body, for our audit work, for this report, or for the opinions we have formed.
For and on behalf of
Calyx House
South Road
Somerset
TA1 3DU
DNA Vetcare Limited
Consolidated Profit and Loss Account for the Year Ended 31 July 2025
|
Note |
2025 |
2024 |
|
|
Turnover |
|
|
|
|
Cost of sales |
( |
( |
|
|
Gross profit |
|
|
|
|
Administrative expenses |
( |
( |
|
|
Other operating income |
|
|
|
|
Operating profit |
|
|
|
|
Income from shares in group undertakings |
|
- |
|
|
Other interest receivable and similar income |
|
|
|
|
Interest payable and similar expenses |
( |
( |
|
|
(1,171,966) |
(822,889) |
||
|
Profit before tax |
|
|
|
|
Tax on profit |
( |
( |
|
|
Profit for the financial year |
|
|
|
|
Profit/(loss) attributable to: |
|||
|
Owners of the company |
|
|
|
|
Minority interests |
|
- |
|
|
|
|
DNA Vetcare Limited
Consolidated Statement of Comprehensive Income for the Year Ended 31 July 2025
|
2025 |
2024 |
|
|
Profit for the year |
|
|
|
Total comprehensive income for the year |
|
|
|
Total comprehensive income attributable to: |
||
|
Owners of the company |
|
|
|
Minority interests |
|
- |
|
|
|
DNA Vetcare Limited
(Registration number: 05185406)
Consolidated Balance Sheet as at 31 July 2025
|
Note |
2025 |
2024 |
|
|
Fixed assets |
|||
|
Intangible assets |
|
|
|
|
Tangible assets |
|
|
|
|
Other financial assets |
2,398 |
2,298 |
|
|
|
|
||
|
Current assets |
|||
|
Stocks |
|
|
|
|
Debtors |
|
|
|
|
Cash at bank and in hand |
|
|
|
|
|
|
||
|
Creditors: Amounts falling due within one year |
( |
( |
|
|
Net current assets |
|
|
|
|
Total assets less current liabilities |
|
|
|
|
Creditors: Amounts falling due after more than one year |
( |
( |
|
|
Provisions for liabilities |
( |
( |
|
|
Net assets |
|
|
|
|
Capital and reserves |
|||
|
Called up share capital |
|
|
|
|
Other reserves |
( |
- |
|
|
Profit and loss account |
|
|
|
|
Equity attributable to owners of the company |
|
|
|
|
Minority interests |
|
- |
|
|
Shareholders' funds |
|
|
Approved and authorised by the
|
|
|
DNA Vetcare Limited
(Registration number: 05185406)
Balance Sheet as at 31 July 2025
|
Note |
2025 |
2024 |
|
|
Fixed assets |
|||
|
Intangible assets |
|
|
|
|
Tangible assets |
|
|
|
|
Investments |
|
|
|
|
Other financial assets |
2,298 |
2,298 |
|
|
|
|
||
|
Current assets |
|||
|
Stocks |
|
|
|
|
Debtors |
|
|
|
|
Cash at bank and in hand |
|
|
|
|
|
|
||
|
Creditors: Amounts falling due within one year |
( |
( |
|
|
Net current assets |
|
|
|
|
Total assets less current liabilities |
|
|
|
|
Creditors: Amounts falling due after more than one year |
( |
( |
|
|
Provisions for liabilities |
( |
( |
|
|
Net assets |
|
|
|
|
Capital and reserves |
|||
|
Called up share capital |
|
|
|
|
Other reserves |
( |
- |
|
|
Retained earnings |
|
|
|
|
Shareholders' funds |
|
|
Approved and authorised by the
|
|
|
DNA Vetcare Limited
Consolidated Statement of Changes in Equity for the Year Ended 31 July 2025
Equity attributable to the parent company
|
Share capital |
Other reserves |
Retained earnings |
Non-controlling interests - Equity |
Total equity |
|
|
At 1 August 2024 |
|
- |
|
- |
|
|
Profit for the year |
- |
- |
|
|
|
|
Dividends |
- |
- |
( |
- |
( |
|
Increase in non-controlling interest in subsidiaries |
- |
- |
- |
|
|
|
Other movements on reserves |
- |
(521,488) |
- |
- |
(521,488) |
|
At 31 July 2025 |
|
( |
|
|
|
|
Share capital |
Retained earnings |
Total equity |
|
|
At 1 August 2023 |
|
|
|
|
Profit for the year |
- |
|
|
|
Dividends |
- |
( |
( |
|
At 31 July 2024 |
100 |
4,603,704 |
4,603,804 |
DNA Vetcare Limited
Statement of Changes in Equity for the Year Ended 31 July 2025
|
Share capital |
Other reserves |
Retained earnings |
Total |
|
|
At 1 August 2024 |
|
- |
|
|
|
Profit for the year |
- |
- |
|
|
|
Dividends |
- |
- |
( |
( |
|
Other movements on reserves |
- |
(521,488) |
- |
(521,488) |
|
At 31 July 2025 |
|
( |
|
|
|
Share capital |
Retained earnings |
Total |
|
|
At 1 August 2023 |
|
|
|
|
Profit for the year |
- |
|
|
|
Dividends |
- |
( |
( |
|
At 31 July 2024 |
100 |
4,375,644 |
4,375,744 |
DNA Vetcare Limited
Consolidated Statement of Cash Flows for the Year Ended 31 July 2025
|
Note |
2025 |
2024 |
|
|
Cash flows from operating activities |
|||
|
Profit for the year |
|
|
|
|
Adjustments to cash flows from non-cash items |
|||
|
Depreciation and amortisation |
|
|
|
|
Profit on disposal of tangible assets |
( |
- |
|
|
Finance income |
( |
( |
|
|
Finance costs |
|
|
|
|
Income tax expense |
|
|
|
|
|
|
||
|
Working capital adjustments |
|||
|
Increase in stocks |
( |
( |
|
|
Increase in debtors |
( |
( |
|
|
Increase in creditors |
|
|
|
|
Cash generated from operations |
|
|
|
|
Income taxes paid |
( |
( |
|
|
Net cash flow from operating activities |
|
|
|
|
Cash flows from investing activities |
|||
|
Interest received |
|
|
|
|
Acquisition of subsidiaries |
( |
- |
|
|
Acquisitions of tangible assets |
( |
( |
|
|
Proceeds from sale of tangible assets |
|
- |
|
|
Acquisition of intangible assets |
( |
( |
|
|
Dividend income |
|
- |
|
|
Acquisition of other financial assets |
( |
( |
|
|
Net cash flows from investing activities |
( |
( |
|
|
Cash flows from financing activities |
|||
|
Interest paid |
( |
( |
|
|
Proceeds from issue of ordinary shares, net of issue costs |
|
- |
|
|
Proceeds from bank borrowing draw downs |
|
|
|
|
Repayment of bank borrowing |
( |
( |
|
|
Proceeds from finance lease draw downs |
|
|
|
|
Payments to finance lease creditors |
( |
( |
|
|
Dividends paid |
( |
( |
|
|
Net cash flows from financing activities |
|
|
|
|
Net increase/(decrease) in cash and cash equivalents |
|
( |
|
|
Cash and cash equivalents at 1 August |
|
|
|
|
Cash and cash equivalents at 31 July |
2,940,594 |
2,244,171 |
|
DNA Vetcare Limited
Statement of Cash Flows for the Year Ended 31 July 2025
|
Note |
2025 |
2024 |
|
|
Cash flows from operating activities |
|||
|
Profit for the year |
|
|
|
|
Adjustments to cash flows from non-cash items |
|||
|
Depreciation and amortisation |
|
|
|
|
Finance income |
( |
( |
|
|
Finance costs |
|
|
|
|
Income tax expense |
|
|
|
|
|
|
||
|
Working capital adjustments |
|||
|
Increase in stocks |
( |
( |
|
|
Increase in debtors |
( |
( |
|
|
Increase in creditors |
|
|
|
|
Cash generated from operations |
|
|
|
|
Income taxes paid |
( |
( |
|
|
Net cash flow from operating activities |
|
|
|
|
Cash flows from investing activities |
|||
|
Interest received |
|
|
|
|
Acquisition of subsidiaries |
( |
- |
|
|
Acquisitions of tangible assets |
( |
( |
|
|
Proceeds from sale of tangible assets |
|
- |
|
|
Acquisition of intangible assets |
( |
( |
|
|
Dividend income |
|
- |
|
|
Acquisition of other financial assets |
( |
( |
|
|
Net cash flows from investing activities |
( |
( |
|
|
Cash flows from financing activities |
|||
|
Interest paid |
( |
( |
|
|
Proceeds from bank borrowing draw downs |
|
|
|
|
Repayment of bank borrowing |
( |
( |
|
|
Proceeds from finance lease draw downs |
|
|
|
|
Payments to finance lease creditors |
( |
( |
|
|
Dividends paid |
( |
( |
|
|
Net cash flows from financing activities |
|
|
|
|
Net increase/(decrease) in cash and cash equivalents |
|
( |
|
|
Cash and cash equivalents at 1 August |
|
|
|
|
Cash and cash equivalents at 31 July |
2,216,089 |
2,098,291 |
|
DNA Vetcare Limited
Notes to the Financial Statements for the Year Ended 31 July 2025
|
General information |
The company is a private company limited by share capital, incorporated in England & Wales (registered number 05185406).
The address of its registered office is:
These financial statements were authorised for issue by the
|
Accounting policies |
Summary of significant accounting policies and key accounting estimates
The principal accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.
Statement of compliance
These financial statements have been prepared in accordance with Financial Reporting Standard 102 - 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' and the Companies Act 2006.
Basis of preparation
These financial statements have been prepared using the historical cost convention except that as disclosed in the accounting policies certain items are shown at fair value.
DNA Vetcare Limited
Notes to the Financial Statements for the Year Ended 31 July 2025
Basis of consolidation
The consolidated financial statements consolidate the financial statements of the company and its subsidiary undertakings drawn up to 31 July 2025.
A subsidiary is an entity controlled by the company. Control is achieved where the company has the power to govern the financial and operating policies of an entity so as to obtain benefits from its activities.
The results of subsidiaries acquired or disposed of during the year are included in the Profit and Loss Account from the effective date of acquisition or up to the effective date of disposal, as appropriate. Where necessary, adjustments are made to the financial statements of subsidiaries to bring their accounting policies into line with those used by the group.
The purchase method of accounting is used to account for business combinations that result in the acquisition of subsidiaries by the group. The cost of a business combination is measured as the fair value of the assets given, equity instruments issued and liabilities incurred or assumed at the date of exchange, plus costs directly attributable to the business combination. Identifiable assets acquired and liabilities and contingent liabilities assumed in a business combination are measured initially at their fair values at the acquisition date. Any excess of the cost of the business combination over the acquirer’s interest in the net fair value of the identifiable assets, liabilities and contingent liabilities recognised is recorded as goodwill.
Inter-company transactions, balances and unrealised gains on transactions between the company and its subsidiaries, which are related parties, are eliminated in full.
Intra-group losses are also eliminated but may indicate an impairment that requires recognition in the consolidated financial statements.
Accounting policies of subsidiaries have been changed where necessary to ensure consistency with the policies adopted by the group. Non-controlling interests in the net assets of consolidated subsidiaries are identified separately from the group’s equity therein. Non-controlling interests consist of the amount of those interests at the date of the original business combination and the non-controlling shareholder’s share of changes in equity since the date of the combination.
Going concern
The financial statements have been prepared on the going concern basis.
In assessing the appropriateness of this basis, the directors have prepared detailed cash flow forecasts and projections for the group covering a period of at least twelve months from the date of approval of these financial statements. These forecasts take into account the group’s current financial position, including its borrowing facilities, and the expected trading performance of the business.
The group has continued to experience strong growth during the year, including the acquisition of additional veterinary practices, and has significant external borrowings in place at the reporting date. The directors have reviewed the terms of these borrowing facilities, including any associated covenants, and are satisfied that the group is expected to remain in compliance with these requirements throughout the forecast period.
The forecasts incorporate reasonable assumptions in respect of trading performance, cost inflation, and capital expenditure, reflecting both historical performance and current market conditions. Sensitivity analysis has been performed to assess the impact of adverse changes in key assumptions, including reductions in revenue growth and increases in operating costs. The results of this analysis indicate that the group would continue to operate within its available facilities under reasonably possible downside scenarios.
Based on this assessment, the directors have a reasonable expectation that the group has adequate resources to continue in operational existence for the foreseeable future. Accordingly, they continue to adopt the going concern basis in preparing the financial statements.
DNA Vetcare Limited
Notes to the Financial Statements for the Year Ended 31 July 2025
Revenue recognition
Revenue is measured at the fair value of consideration received or receivable, net of discounts, rebates, and value added tax. Revenue is recognised when it is probable that economic benefits will flow to the group and the amount of revenue can be measured reliably.
Veterinary services
Revenue from veterinary services, including consultations, treatments, and surgical procedures, is recognised at the point in time when the service is provided to the customer.
Monthly healthcare plans
The group offers customers monthly subscription plans under which they pay a fixed monthly fee in exchange for specified routine treatments and products over the contract period. Income from these plans is recognised in the period to which the services relate, based on the proportion of services delivered compared with the customer’s total entitlement under the plan. Amounts received in advance for services to be delivered in future periods are recognised as deferred income. Where services have been provided but payment has not yet been received, income is recognised as accrued income.
Pharmaceutical sales
Revenue from the sale of pharmaceutical products is recognised at the point when the significant risks and rewards of ownership are transferred to the customer, which is typically when the goods are supplied and the customer takes delivery.
Other Income
Interest income is recognised on an accruals basis using the effective interest method.
Contract Liabilities and Assets
Amounts invoiced in advance of the delivery of goods or services are recorded as deferred income. Unbilled amounts relating to services provided are recorded as accrued income.
Tax
The tax expense for the period comprises current and deferred tax. Tax is recognised in profit or loss, except that a change attributable to an item of income or expense recognised as other comprehensive income is also recognised directly in other comprehensive income.
The current tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the reporting date in the countries where the company operates and generates taxable income.
Deferred tax is recognised on temporary differences arising between the tax bases of assets and liabilities and their carrying amounts in the financial statements and on unused tax losses or tax credits in the company. Deferred income tax is determined using tax rates and laws that have been enacted or substantively enacted by the reporting date.
The carrying amount of deferred tax assets are reviewed at each reporting date and a valuation allowance is set up against deferred tax assets so that the net carrying amount equals the highest amount that is more likely than not to be recovered based on current or future taxable profit.
Tangible assets
Tangible assets are stated in the statement of financial position at cost, less any subsequent accumulated depreciation and subsequent accumulated impairment losses.
DNA Vetcare Limited
Notes to the Financial Statements for the Year Ended 31 July 2025
Depreciation
Depreciation is charged so as to write off the cost of assets, other than land and properties under construction over their estimated useful lives, as follows:
|
Asset class |
Depreciation method and rate |
|
Freehold land and buildings |
2% straight line |
|
Long leasehold land and buildings |
Over the term of the lease |
|
Plant and machinery |
15% reducing balance |
|
Motor vehicles |
25% reducing balance |
|
Office equipment |
33% straight line |
Business combinations
Business combinations are accounted for using the purchase method. The consideration for each acquisition is measured at the aggregate of the fair values at acquisition date of assets given, liabilities incurred or assumed, and equity instruments issued by the group in exchange for control of the acquired, plus any costs directly attributable to the business combination. When a business combination agreement provides for an adjustment to the cost of the combination contingent on future events, the group includes the estimated amount of that adjustment in the cost of the combination at the acquisition date if the adjustment is probable and can be measured reliably.
Goodwill
Goodwill is initially recognised as an asset at cost and is subsequently measured at cost less accumulated amortisation and accumulated impairment losses.
Goodwill is amortised on a straight-line basis over its estimated useful economic life of 10 years.
This period is considered appropriate having regard to the nature of the acquired businesses, which are established veterinary practices with stable customer bases and long-term client relationships. The directors consider that the benefits arising from these acquisitions, including customer retention, brand reputation and integration into the group’s network, will be realised over a period in excess of five years.
Amortisation
Amortisation is provided on intangible assets so as to write off the cost, less any estimated residual value, over their useful life as follows:
|
Asset class |
Amortisation method and rate |
|
Goodwill |
10% straight line |
Investments
Investments in equity shares where the fair value can be measured reliably are initially measured at fair value, with changes in fair value recognised in the profit or loss account. Investments in equity shares where fair value cannot be measured reliably are measured at cost less impairment.
Cash and cash equivalents
Cash and cash equivalents comprise cash on hand and call deposits, and other short-term highly liquid investments that are readily convertible to a known amount of cash and are subject to an insignificant risk of change in value.
Trade debtors
Trade debtors are amounts due from customers for merchandise sold or services performed in the ordinary course of business.
Trade debtors are recognised initially at the transaction price. They are subsequently measured at amortised cost using the effective interest method, less provision for impairment. A provision for the impairment of trade debtors is established when there is objective evidence that the group will not be able to collect all amounts due according to the original terms of the receivables.
DNA Vetcare Limited
Notes to the Financial Statements for the Year Ended 31 July 2025
Stocks
Stocks are stated at the lower of cost and estimated selling price less costs to sell.
Trade creditors
Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Accounts payable are classified as current liabilities if the group does not have an unconditional right, at the end of the reporting period, to defer settlement of the creditor for at least twelve months after the reporting date. If there is an unconditional right to defer settlement for at least twelve months after the reporting date, they are presented as non-current liabilities.
Trade creditors are recognised initially at the transaction price and subsequently measured at amortised cost using the effective interest method.
Borrowings
Interest-bearing borrowings are initially recorded at fair value, net of transaction costs. Interest-bearing borrowings are subsequently carried at amortised cost, with the difference between the proceeds, net of transaction costs, and the amount due on redemption being recognised as a charge to the profit and loss account over the period of the relevant borrowing.
Interest expense is recognised on the basis of the effective interest method and is included in interest payable and similar charges.
Borrowings are classified as current liabilities unless the group has an unconditional right to defer settlement of the liability for at least twelve months after the reporting date.
Leases
Leases in which substantially all the risks and rewards of ownership are retained by the lessor are classified as operating leases. Payments made under operating leases are charged to profit or loss on a straight-line basis over the period of the lease.
Leases are classified as finance leases whenever the terms of the lease transfer substantially all the risks and rewards of ownership to the lessee.
Assets held under finance leases are recognised at the lower of their fair value at inception of the lease and the present value of the minimum lease payments. These assets are depreciated on a straight-line basis over the shorter of the useful life of the asset and the lease term. The corresponding liability to the lessor is included in the balance sheet as a finance lease obligation.
Lease payments are apportioned between finance costs in the profit and loss account and reduction of the lease obligation so as to achieve a constant periodic rate of interest on the remaining balance of the liability.
Share capital
Ordinary shares are classified as equity. Equity instruments are measured at the fair value of the cash or other resources received or receivable, net of the direct costs of issuing the equity instruments. If payment is deferred and the time value of money is material, the initial measurement is on a present value basis.
Dividends
Dividend distribution to the group’s shareholders is recognised as a liability in the financial statements in the reporting period in which the dividends are declared.
DNA Vetcare Limited
Notes to the Financial Statements for the Year Ended 31 July 2025
Defined contribution pension obligation
A defined contribution plan is a pension plan under which fixed contributions are paid into a pension fund and the group has no legal or constructive obligation to pay further contributions even if the fund does not hold sufficient assets to pay all employees the benefits relating to employee service in the current and prior periods.
Contributions to defined contribution plans are recognised as employee benefit expense when they are due. If contribution payments exceed the contribution due for service, the excess is recognised as a prepayment.
|
Judgements in applying accounting policies and key sources of estimation uncertainty |
The preparation of the financial statements requires management to make judgements, estimates and assumptions that affect the amounts reported for assets and liabilities as at the balance sheet date and the amounts reported for revenues and expenses during the year. However, the nature of estimation means that actual outcomes could differ from those estimates.
The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised if the revision affects that period, or in the period of revision and future periods if the revision affects both current and future periods. The critical judgements and key sources of estimation uncertainty that have a significant effect on the amounts recognised in the financial statements are described below.
Critical judgements
Depreciation rates and residual values
Tangible fixed assets are depreciated over their useful economic lives taking into account residual values, where appropriate. The actual lives of the assets and residual values are assessed annually and may vary depending on a number of factors. In re-assessing assets lives, factors such as technological innovation, product life cycles and maintenance programmes are taken into account. Residual value assessments consider issues such as future market conditions, the remaining life of the asset and projected disposal values.
Sources of estimation uncertainty
Impairment of fixed assets
The company determines whether there are indicators of impairment of tangible asset. Factors taken into account consideration in reaching such a decision include the economic viability and expected future financial performance of the asset.
Stock provision
The company determines whether there are conditions that exist at the balance sheet date that indicates that the net realisable value of individual stock lines are less than the carrying value. Such indicators include post year end sales, and market demand.
Bad debt provision
The company determines whether there are conditions that exist at the balance sheet date that indicates the recoverable value of debtors is less than the carrying value. Such indicators include post year end cash receipts, and customer sales activity.
DNA Vetcare Limited
Notes to the Financial Statements for the Year Ended 31 July 2025
|
Turnover |
The analysis of the group's revenue for the year from continuing operations is as follows:
|
2025 |
2024 |
|
|
Small animal turnover |
|
|
All turnover is generated in the United Kingdom.
|
Other operating income |
The analysis of the group's other operating income for the year is as follows:
|
2025 |
2024 |
|
|
Miscellaneous other operating income |
|
|
|
Operating profit |
Arrived at after charging/(crediting)
|
2025 |
2024 |
|
|
Depreciation expense |
|
|
|
Amortisation expense |
|
|
|
Operating lease expense - plant and machinery |
|
|
|
Other interest receivable and similar income |
|
2025 |
2024 |
|
|
Interest income on bank deposits |
|
|
|
Other finance income |
|
|
|
|
|
|
Interest payable and similar expenses |
|
2025 |
2024 |
|
|
Interest on obligations under finance leases and hire purchase contracts |
|
|
|
Interest expense on other finance liabilities |
|
|
|
|
|
DNA Vetcare Limited
Notes to the Financial Statements for the Year Ended 31 July 2025
|
Staff costs |
The aggregate payroll costs (including directors' remuneration) were as follows:
|
2025 |
2024 |
|
|
Wages and salaries |
|
|
|
Other employee expense |
|
|
|
|
|
The average number of persons employed by the group (including directors) during the year, analysed by category was as follows:
|
2025 |
2024 |
|
|
Other departments |
|
|
|
|
|
|
Directors' remuneration |
The directors' remuneration for the year was as follows:
|
2025 |
2024 |
|
|
Remuneration |
|
|
|
Auditors' remuneration |
|
2025 |
2024 |
|
|
Audit of these financial statements |
48,950 |
41,000 |
DNA Vetcare Limited
Notes to the Financial Statements for the Year Ended 31 July 2025
|
Taxation |
Tax charged/(credited) in the consolidated profit and loss account
|
2025 |
2024 |
|
|
Current taxation |
||
|
UK corporation tax |
|
|
|
UK corporation tax adjustment to prior periods |
|
( |
|
897,771 |
406,327 |
|
|
Deferred taxation |
||
|
Arising from origination and reversal of timing differences |
|
|
|
Tax expense in the income statement |
|
|
The tax on profit before tax for the year is the same as the standard rate of corporation tax in the UK (2024 - the same as the standard rate of corporation tax in the UK) of
The differences are reconciled below:
|
2025 |
2024 |
|
|
Profit before tax |
|
|
|
Corporation tax at standard rate |
|
|
|
Increase/(decrease) in UK and foreign current tax from adjustment for prior periods |
|
( |
|
Tax increase/(decrease) from effect of capital allowances and depreciation |
|
( |
|
Effect of revenues exempt from taxation |
( |
- |
|
Effect of expense not deductible in determining taxable profit (tax loss) |
|
|
|
Deferred tax expense |
|
|
|
Total tax charge |
|
|
DNA Vetcare Limited
Notes to the Financial Statements for the Year Ended 31 July 2025
|
Intangible assets |
Group
|
Goodwill |
Total |
|
|
Cost or valuation |
||
|
At 1 August 2024 |
|
|
|
Additions acquired separately |
|
|
|
At 31 July 2025 |
|
|
|
Amortisation |
||
|
At 1 August 2024 |
|
|
|
Amortisation charge |
|
|
|
At 31 July 2025 |
|
|
|
Carrying amount |
||
|
At 31 July 2025 |
|
|
|
At 31 July 2024 |
|
|
Company
|
Goodwill |
Total |
|
|
Cost or valuation |
||
|
At 1 August 2024 |
|
|
|
Additions acquired separately |
|
|
|
At 31 July 2025 |
|
|
|
Amortisation |
||
|
At 1 August 2024 |
|
|
|
Amortisation charge |
|
|
|
At 31 July 2025 |
|
|
|
Carrying amount |
||
|
At 31 July 2025 |
|
|
|
At 31 July 2024 |
|
|
DNA Vetcare Limited
Notes to the Financial Statements for the Year Ended 31 July 2025
|
Tangible assets |
Group
|
Land and buildings |
Motor vehicles |
Office equipment |
Plant and machinery |
Total |
|
|
Cost or valuation |
|||||
|
At 1 August 2024 |
|
|
259,571 |
4,106,320 |
|
|
Additions |
|
|
63,307 |
1,360,352 |
|
|
Disposals |
( |
- |
- |
- |
( |
|
At 31 July 2025 |
|
|
322,878 |
5,466,672 |
|
|
Depreciation |
|||||
|
At 1 August 2024 |
|
|
236,542 |
1,573,629 |
|
|
Charge for the year |
|
|
38,554 |
486,053 |
|
|
Eliminated on disposal |
( |
- |
- |
- |
( |
|
At 31 July 2025 |
|
|
275,096 |
2,059,682 |
|
|
Carrying amount |
|||||
|
At 31 July 2025 |
|
|
47,782 |
3,406,990 |
|
|
At 31 July 2024 |
|
|
23,029 |
2,467,589 |
|
Included within the net book value of land and buildings above is £11,912,966 (2024 - £4,733,873) in respect of freehold land and buildings and £1,181,886 (2024 - £1,231,183) in respect of long leasehold land and buildings. During the year, certain properties were reclassified between leasehold and freehold. The amounts involved are not material to the financial statements.
DNA Vetcare Limited
Notes to the Financial Statements for the Year Ended 31 July 2025
Company
|
Land and buildings |
Motor vehicles |
Office equipment |
Plant and machinery |
Total |
|
|
Cost or valuation |
|||||
|
At 1 August 2024 |
|
|
259,254 |
3,939,378 |
|
|
Additions |
|
|
63,307 |
1,308,257 |
|
|
Disposals |
( |
- |
- |
- |
( |
|
At 31 July 2025 |
|
|
322,561 |
5,247,635 |
|
|
Depreciation |
|||||
|
At 1 August 2024 |
|
|
236,225 |
1,471,789 |
|
|
Charge for the year |
|
|
38,554 |
467,362 |
|
|
Eliminated on disposal |
( |
- |
- |
- |
( |
|
At 31 July 2025 |
|
|
274,779 |
1,939,151 |
|
|
Carrying amount |
|||||
|
At 31 July 2025 |
|
|
47,782 |
3,308,484 |
|
|
At 31 July 2024 |
|
|
23,029 |
2,467,589 |
|
Included within the net book value of land and buildings above is £11,912,966 (2024 - £4,733,873) in respect of freehold land and buildings and £1,181,886 (2024 - £1,231,183) in respect of long leasehold land and buildings. During the year, certain properties were reclassified between leasehold and freehold. The amounts involved are not material to the financial statements.
DNA Vetcare Limited
Notes to the Financial Statements for the Year Ended 31 July 2025
|
Investments |
Group
Details of undertakings
Details of the investments (including principal place of business of unincorporated entities) in which the group holds 20% or more of the nominal value of any class of share capital are as follows:
|
Undertaking |
Registered office |
Holding |
Proportion of voting rights and shares held |
|
|
2025 |
2024 |
|||
|
Subsidiary undertakings |
||||
|
|
85 Earls Court Road
|
|
|
|
|
|
3 Station Parade Burlington Lane
|
|
|
|
|
|
335 Lower Addiscombe Road
|
|
|
|
|
|
105 Humber Road
|
|
|
|
|
|
105 Humber Road
|
|
|
|
|
|
105 Humber Road
|
|
|
|
|
|
105 Humber Road
|
|
|
|
DNA Vetcare Limited
Notes to the Financial Statements for the Year Ended 31 July 2025
Subsidiary undertakings
|
Abingdon Veterinary Clinics Limited The principal activity of Abingdon Veterinary Clinics Limited is |
|
Grove Park Veterinary Clinic Limited The principal activity of Grove Park Veterinary Clinic Limited is |
|
Vetscriptions Limited The principal activity of Vetscriptions Limited is |
|
Kitten to Cat Clinic Limited The principal activity of Kitten to Cat Clinic Limited is |
|
Old Registry DNA Vetcare Ltd The principal activity of Old Registry DNA Vetcare Ltd is |
|
Registry Surgery Limited The principal activity of Registry Surgery Limited is |
|
Animalism Limited The principal activity of Animalism Limited is |
|
Business combinations |
During the year, the group acquired a number of veterinary practices as part of its strategy to expand its operations and geographical footprint. The acquisition has been accounted for using the purchase method.
Details of the aggregate acquisitions are as follows:
|
Book value |
Fair value |
|
|
Assets and liabilities acquired |
||
|
Tangible assets |
595,733 |
|
|
Goodwill |
991,758 |
|
|
Total consideration |
1,587,491 |
1,587,491 |
|
|
||
Goodwill represents the value of the assembled workforce, expected synergies from integration into the group, and the strategic locations of the acquired practices.
The acquired businesses contributed revenue of £320,837 and profit before tax of £13,050 for the period from acquisition to 31 July 2025.
DNA Vetcare Limited
Notes to the Financial Statements for the Year Ended 31 July 2025
|
Other financial assets |
Group
|
Financial assets at cost less impairment |
Total |
|
|
Non-current financial assets |
||
|
Cost or valuation |
||
|
At 1 August 2024 |
2,298 |
2,298 |
|
Additions |
100 |
100 |
|
At 31 July 2025 |
2,398 |
2,398 |
|
Carrying amount |
||
|
At 31 July 2025 |
|
2,398 |
Company
|
Financial assets at cost less impairment |
Total |
|
|
Non-current financial assets |
||
|
Cost or valuation |
||
|
At 1 August 2024 |
2,298 |
2,298 |
|
At 31 July 2025 |
2,298 |
2,298 |
|
Carrying amount |
||
|
At 31 July 2025 |
|
2,298 |
|
Stocks |
|
Group |
Company |
|||
|
2025 |
2024 |
2025 |
2024 |
|
|
Stock |
|
|
|
|
DNA Vetcare Limited
Notes to the Financial Statements for the Year Ended 31 July 2025
|
Debtors |
|
Group |
Company |
||||
|
Current |
Note |
2025 |
2024 |
2025 |
2024 |
|
Trade debtors |
|
|
|
|
|
|
Amounts owed by related parties |
|
|
|
|
|
|
Other debtors |
|
|
|
|
|
|
Prepayments |
|
|
|
|
|
|
Corporation tax asset |
|
|
|
|
|
|
|
|
|
|
||
|
Cash and cash equivalents |
|
Group |
Company |
|||
|
2025 |
2024 |
2025 |
2024 |
|
|
Cash on hand |
|
|
|
|
|
Cash at bank |
|
|
|
|
|
|
|
|
|
|
|
Creditors |
|
Group |
Company |
||||
|
Note |
2025 |
2024 |
2025 |
2024 |
|
|
Due within one year |
|||||
|
Bank loans and overdrafts |
|
|
|
|
|
|
Trade creditors |
|
|
|
|
|
|
Amounts owed to group undertakings, undertakings in which a company has a participating interest and related parties, |
|
|
|
|
|
|
Social security and other taxes |
|
|
|
|
|
|
Outstanding defined contribution pension costs |
|
|
|
|
|
|
Other payables |
|
|
|
|
|
|
Accruals |
|
|
|
|
|
|
Corporation Tax Liability |
368,569 |
- |
- |
- |
|
|
|
|
|
|
||
|
Due after one year |
|||||
|
Bank loans and overdrafts |
|
|
|
|
|
DNA Vetcare Limited
Notes to the Financial Statements for the Year Ended 31 July 2025
|
Provisions for liabilities |
Group
|
Deferred tax |
Total |
|
|
At 1 August 2024 |
|
|
|
Additional provisions |
|
|
|
Increase (decrease) through business combinations |
|
|
|
At 31 July 2025 |
|
|
|
|
||
Company
|
Deferred tax |
Total |
|
|
At 1 August 2024 |
|
|
|
Additional provisions |
|
|
|
Increase (decrease) through business combinations |
|
|
|
At 31 July 2025 |
|
|
|
|
||
|
Pension and other schemes |
Defined contribution pension scheme
The group operates a defined contribution pension scheme. The pension cost charge for the year represents contributions payable by the group to the scheme and amounted to £341,912 (2024 - £262,917).
Contributions totalling £
|
Share capital |
Allotted, called up and fully paid shares
|
2025 |
2024 |
|||
|
No. |
£ |
No. |
£ |
|
|
|
|
40 |
|
40 |
|
|
|
40 |
|
40 |
|
|
|
10 |
|
10 |
|
|
|
10 |
|
10 |
|
|
|
|
|
|
DNA Vetcare Limited
Notes to the Financial Statements for the Year Ended 31 July 2025
|
Loans and borrowings |
Non-current loans and borrowings
|
Group |
Company |
|||
|
2025 |
2024 |
2025 |
2024 |
|
|
Bank borrowings |
|
|
|
|
|
Hire purchase contracts |
|
|
|
|
|
|
|
|
|
|
|
Group |
Company |
|||
|
2025 |
2024 |
2025 |
2024 |
|
|
Current loans and borrowings |
||||
|
Bank borrowings |
|
|
|
|
|
Hire purchase contracts |
|
|
|
|
|
|
|
|
|
|
Bank loans within the group have a carrying amount at the year end of £21,127,687 (2024: £12,934,282). Bank loans are secured by fixed and floating charges over all the company's assets.
Company
Included in the loans and borrowings are the following amounts due after more than five years:
|
2025 |
2024 |
|
|
After more than five years by instalments |
|
|
|
- |
- |
DNA Vetcare Limited
Notes to the Financial Statements for the Year Ended 31 July 2025
|
Commitments |
Company
Amounts not provided for in the balance sheet:
Due within a year: £762,493 (2024 - £637,043)
Due within 1-5 years: £1,167,359 (2024 - £1,284,822)
Due over 5 years: £1,108,955 (2024 - £827,404)
The total amount of other financial commitments not provided for in the financial statements was £3,038,806 (2024 - £2,749,269). The other financial commitments are leases the company has entered into on properties that the business operates from.
|
Parent company profit for the year |
The Company has taken advantage of the exemption allowed under section 408 of the Companies Act 2006 and has not presented its own Statement of comprehensive income in these financial statements. The profit after tax of the parent Company for the year was £1,137,491 (2024 - £1,184,825).
|
Related party transactions |
Group
Key management compensation
|
2025 |
2024 |
|
|
Salaries and other short term employee benefits |
|
|
|
Transactions with directors |
|
2025 |
At 1 August 2024 |
Advances to director |
Repayments by director |
At 31 July 2025 |
|
Mr S D Walker |
||||
|
Director's loan account |
- |
|
( |
- |
|
2024 |
At 1 August 2023 |
Advances to director |
Repayments by director |
At 31 July 2024 |
|
Mr A G Van Heerden |
||||
|
Director's loan account |
- |
|
( |
- |
|
Mr S D Walker |
||||
|
Director's loan account |
|
|
( |
- |